We thank Huixun Jia and Xiaodong Sun for their perspective on our study.1 The goals of this first-in-human trial were to identify safe doses of RGX-314 and an optimised protocol for advanced studies.

In our iMac M4 review, we gave the Editor's Choice all-in-one four stars for delivering better performance than any iMac to ...

The Laser Vision Correction Center of New Jersey is the first practice in New Jersey to offer the Valeda Light Delivery ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

The biggest discount of $550 comes if you have a MacBook Air M3 to hand over, but you also get $500 for the M2 version and up ...

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...

Company will discuss its patented remote monitoring high-resolution retinal imaging system RetinalCam™ and associated ...